Interventional2022-12-16T17:04:01+03:00
Studies on…
sepsis and severe infections
systemic inflammatory disorders
23April, 2021

FERMIN

April 23rd, 2021|Tags: |

Completed study Official Study Title FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019 (COVID-19): A randomized controlled trial (FERMIN trial) Brief Description FERMIN is a randomized clinical trial aiming to assess the clinical impact of fenofibrate to improve clinical outcomes in patients with COVID-19. Details Status: Completed Study Type: Interventional (Clinical Trial)

1January, 2021

ACCESS

January 1st, 2021|Tags: , |

Completed study Official Study Title A randomized clinical trial of oral Clarithromycin in Community-acquired pneumonia to attenuatE inflammatory responseS and improve outcomeS Brief Description Based on evidence coming from observational studies that addition of macrolides in the treatment regimen of community-acquired pneumonia (CAP) exhibits some anti-inflammatory mode of action, this RCT is aiming to

1December, 2020

SAVE-MORE

December 1st, 2020|Tags: , |

Completed study Official Study Title suPAR-guided Anakinra treatment for Validation of the risk and Early Management Of seveRE respiratory failure by COVID-19: The SAVE-MORE Double-blind, Randomized, Phase III Confirmatory Trial Brief Description SAVE-MORE is a double-blind randomized clinical trial aiming to study the early treatment of patients with COVID-19 pneumonia with anakinra guided by

1June, 2020

ACTIVATE-II

June 1st, 2020|Tags: , |

Completed study Official Study Title A randomized clinical trial for enhanced trained immune responses through Bacillus Calmette-Guérin vaccination to prevent infections by COVID-19 Brief Description ACTIVATE-II is a randomized clinical trial aiming to investigate if the developing concept of trained immunity i.e. the memory of the innate immune system coming after vaccination exists in

1May, 2020

ACHIEVE

May 1st, 2020|Tags: , |

Completed study Official Study Title Anti-inflammatory ClaritHromycin to ImprovE SARS-CoV-2 (COVID-19) infection Early: The ACHIEVE open-label non-randomized clinical trial Brief Description ACHIEVE is an open non-randomized clinical trial aiming to prove that the addition of oral clarithromycin to treatment regimen of COVID-19 is associated with early clinical improvement and attenuation of the high inflammatory

1April, 2020

SAVE

April 1st, 2020|Tags: , |

Completed study Official Study Title suPAR-guided Anakinra treatment for Validation of the risk and Early management of severe respiratory failure by COVID-19: the SAVE open-label, non-randomized single-arm trial Brief Description SAVE is an open non-randomized clinical trial aiming to study the early treatment of patients with COVID-19 pneumonia with anakinra guided by the biomarker

Go to Top